Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chordia Therapeutics Inc

http://www.chordiatherapeutics.com

Latest From Chordia Therapeutics Inc

Chordia Looks To Forge Own Path In Oncology

Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.

Japan Commercial

Asia Deal Watch: Astellas Acquires Global Rights To KaliVir Oncolytic Virus Candidate

Plus deals involving SELLAS/3D Medicines, Kyowa Kirin/InveniAI, JW/Voronoi, Y-mAbs/Takeda, Horizon Discovery/Sanyou, Sentinel Oncology/PharmaEngine

Deals Business Strategies

GNC’s Deadline To Refinance Or Restructure Delayed Until August

GNC had faced a springing maturity date of 16 May for payments to reduce its debt of more than $865m in convertible notes and other debts from credit facilities to less than $50m.

Financing Dietary Supplements

GNC's Slump Leads To Delist Notice For Its Stock

GNC's 30 trading-day average closing share price through 21 April was 56 cents and the average market capitalization was around $47.3m; the firm's last reported stockholders’ equity through December 2019 was a debt of around $207.3m.

Financing Sales & Earnings
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register